Liling Bio is a TCR-T cell therapy and TCR dual-antibody drug developer, dedicated to the development of personalized T-cell therapy (Personalized TCR-T) and TCR dual-antibody drugs. The company has multiple technology platforms such as TCR rapid cloning and screening technology that does not rely on gene synthesis, a variety of optimized aAPC models, immune cells that secrete single domain antibodies, and optimized TCR double antibody structure, which can further eliminate the existing TCR related drugs. short board. Recently, Liling Bio announced the completion of an angel round of financing of tens of millions of yuan, which was jointly invested by Mint Angel Fund and Yuansheng Venture Capital. The funds obtained in this round are mainly used for the improvement of the TCR technology platform, the promotion of related project pipelines and team building.
This article is reproduced from: https://www.itjuzi.com/investevent/13639119
This site is for inclusion only, and the copyright belongs to the original author.